Literature DB >> 8508366

Oligodendroglioma. The Princess Margaret Hospital experience (1958-1984).

T S Nijjar1, W J Simpson, T Gadalla, M McCartney.   

Abstract

BACKGROUND: Oligodendrogliomas are rare central nervous system (CNS) tumors. Although surgery remains the primary treatment, the role of postoperative radiation treatment remains a matter of controversy. This study assesses whether postoperative radiation improves survival and local tumor control when compared with surgical treatment alone.
METHODS: The medical records of 72 patients with the diagnosis of oligodendroglioma, registered at the Princess Margaret Hospital (PMH) between 1958 and 1984, were reviewed retrospectively. The data of 68 patients were evaluated, but 4 patients were excluded from the analysis because of inadequate follow-up. The median follow-up period at the time of analysis was 7.5 years. Tumors were classified as oligodendrogliomas, malignant oligodendrogliomas, or mixed oligoastrocytomas. Fifty-eight (85%) patients received postoperative irradiation at initial diagnosis, and 10 (15%) patients were treated with surgery alone. In most patients (76%), the radiation dose was 5000 cGy in 25 fractions given during a period of 5 weeks.
RESULTS: Five- and 10-year overall survival was 66% and 30%, respectively. Forty-two (62.0%) patients experienced disease relapse during the follow-up period. The median time to relapse from initial diagnosis was 2.6 years. Most tumor recurrences were at the primary site. Two patients developed distant metastasis within the CNS axis. Histologic subtype was the only significant prognostic factor for survival. The patients with oligodendroglioma and malignant oligodendroglioma had 5-year survival rates of 73% and 32%, respectively (P = 0.033).
CONCLUSIONS: The authors drew three conclusions. (1) Most patients eventually died with this tumor from local recurrence without distant metastasis. Local tumor control remains the major problem. (2) Tumor histologic subtype is a significant prognostic factor. (3) No statistically significant benefit can be attributed to postoperative irradiation; however, the number of patients not receiving radiation therapy was small (10). Thus, the role of radiation therapy remains a matter of controversy.

Entities:  

Mesh:

Year:  1993        PMID: 8508366     DOI: 10.1002/1097-0142(19930615)71:12<4002::aid-cncr2820711234>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Radiation therapy for incompletely resected supratentorial low-grade glioma in adults.

Authors:  B Jeremic; M Bamberg
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

2.  Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

Authors:  C Daumas-Duport; M L Tucker; H Kolles; P Cervera; F Beuvon; P Varlet; N Udo; M Koziak; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

3.  Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

Authors:  C Daumas-Duport; P Varlet; M L Tucker; F Beuvon; P Cervera; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

4.  Comparative genetic analysis of metachronous anaplastic oligoastrocytomas with extended recurrence-free interval.

Authors:  Ramon Martinez; Hans-Konrad Schackert; Matthias Kirsch; Werner Paulus; Stefan Joos; Gabriele Schackert
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

5.  Blood flow and metabolism of oligodendrogliomas: a positron emission tomography study with kinetic analysis of 18F-fluorodeoxyglucose.

Authors:  K Mineura; H Shioya; M Kowada; T Ogawa; J Hatazawa; K Uemura
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

Review 6.  Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis.

Authors:  Michael G Brandel; Ali A Alattar; Brian R Hirshman; Xuezhi Dong; Kate T Carroll; Mir Amaan Ali; Bob S Carter; Clark C Chen
Journal:  J Neurooncol       Date:  2017-04-24       Impact factor: 4.130

Review 7.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

8.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  Role of exclusive chemotherapy as first line treatment in oligodendroglioma.

Authors:  Marie Pierre Sunyach; Anne Jouvet; David Perol; Emmanuel Jouanneau; Jacques Guyotat; Laurence Gignoux; Christian Carrie; Didier Frappaz
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

10.  Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.

Authors:  Chul-Kee Park; Se-Hoon Lee; Jung Ho Han; Chae-Yong Kim; Dong-Wan Kim; Sun Ha Paek; Dong Gyu Kim; Dae Seog Heo; Il Han Kim; Hee-Won Jung
Journal:  BMC Cancer       Date:  2009-12-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.